2025-08-19 - Analysis Report
Okay, here's a report analyzing Transmedics Group Inc (TMDX) based on the provided data.

## TMDX (Transmedics Group Inc) Performance Analysis

**Transmedics Group Inc is a medical technology company focused on preserving organ viability for transplantation.**

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 248.41%
*   **VOO Cumulative Return:** 72.41%
*   **Absolute Divergence (TMDX - VOO):** 190.4%
*   **Relative Divergence:** 71.3%

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the observed period. The absolute divergence is substantial, and the relative divergence indicates that TMDX's outperformance is positioned in the upper range of its historical performance relative to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2019-2021  | -4.0%  | 63.4%  | -52.0% | 0.0  | 0.7    |
| 2020-2022  | 140.0% | 68.3%  | 138.0% | 0.1  | 2.1    |
| 2021-2023  | 95.0%  | 69.4%  | 77.0%  | 0.2  | 2.7    |
| 2022-2024  | 147.0% | 82.8%  | 121.0% | 0.2  | 2.1    |
| 2023-2025  | 130.0% | 82.8%  | 77.0%  | 0.5  | 4.3    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate varies significantly, indicating periods of both negative and substantial positive growth.
*   **MDD:** Maximum Drawdown figures are quite high, suggesting significant volatility and risk.
*   **Alpha:** Alpha is consistently positive, indicating that the stock has outperformed its benchmark, but decreased significantly in 2023-2025.
*   **Beta:** Beta values range from 0.0 to 0.5. In the later years, the beta increased, showing higher correlation with the market.

### 2. Recent Price Action

*   **Current Price:** $125.65
*   **Previous Close:** $127.55
*   **Price Change:** -1.49
*   **5-day Moving Average:** $129.22
*   **20-day Moving Average:** $118.24
*   **60-day Moving Average:** $124.56

**Analysis:**

*   The current price is slightly lower than the previous close.
*   The 5-day moving average is above the current price, suggesting a recent downtrend.
*   The 20-day moving average is significantly below the current price, indicating a potential longer-term uptrend that might be losing momentum.
*   The 60-day moving average is around the same as the current price.

### 3. Market Risk Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3285 (Low Risk)
*   **RSI:** 66.90
*   **PPO:** 1.28
*   **Hybrid Signal:** cash_0%_Buy 90% of cash
*   **Delta Previous Relative Divergence (20-day):** 9.2 (+), suggesting a short-term upward trend in relative performance.
*   **Expected Return:** 45.1% (long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** The low-risk MRI suggests the stock is relatively stable compared to overall market conditions.
*   **RSI:** An RSI of 66.90 is approaching overbought conditions (above 70).
*   **PPO:** A positive PPO indicates that the shorter-term moving average is above the longer-term moving average, implying an uptrend.
*   **Price Change Alert:** The price change of -1.49 might indicate a slight downward pressure on the stock price currently.
*   **Expected Return:** The high expected return suggests significant potential for long-term outperformance.

### 4. Recent News & Significant Events

*   **[2025-08-16]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-18]:** Analysts discussing performance in the context of industry and economic trends.
*   **[2025-08-15]:** Notable stock volatility.
*   **[2025-08-19]:** Experts highlighting risks and opportunities, advising monitoring of news and announcements.

**Analysis:** The news indicates that TMDX is experiencing volatility and is subject to significant market attention and potential developments. Investors should stay informed about company-specific news and broader market trends.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.70 | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** TMDX has consistently beaten EPS expectations in recent quarters, with a significant beat in the most recent quarter. This positive earnings surprise could be driving positive investor sentiment.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $0.16B     | 61.38%        |
| 2025-03-31 | $0.14B     | 61.47%        |
| 2024-12-31 | $0.12B     | 59.21%        |
| 2024-09-30 | $0.11B     | 55.94%        |
| 2024-06-30 | $0.11B     | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE     |
|------------|------------|---------|
| 2025-06-30 | $0.32B     | 10.97%  |
| 2025-03-31 | $0.27B     | 9.64%   |
| 2024-12-31 | $0.23B     | 3.00%   |
| 2024-09-30 | $0.21B     | 2.01%   |
| 2024-06-30 | $0.19B     | 6.42%   |

**Analysis:**

*   **Revenue:** Revenue has been consistently increasing over the past five quarters, indicating strong growth.
*   **Profit Margin:** Profit margins are high and relatively stable, showing efficient operations.
*   **Equity:** Equity has been growing, reflecting the company's increasing value.
*   **ROE:** Return on Equity has significantly increased over the past few quarters, indicating improved profitability and efficiency in using shareholder equity.

### 7. Overall Summary

TMDX has demonstrated exceptional growth and outperformance relative to the S&P 500. Recent earnings beats, increasing revenue, and high-profit margins suggest strong fundamentals. However, the stock exhibits high volatility and is subject to significant market news and events. While the MRI indicates low market risk, the RSI is approaching overbought levels, and recent price action suggests a slight pullback.  The high expected return suggests continued long-term potential, but investors should be aware of the inherent risks and closely monitor company-specific and market-wide developments. The hybrid signal recommends to buy 90% of cash, which shows it is the right time to purchase.

